Publications

  1. Scherber RM, Geyer HL, Mesa RA. Quality of life in MPN comes of age as a therapeutic target. Curr Hematologic Malignancy Reports. 2014 Sep 28.
  2. Scherber RM, Geyer HL, Mesa RA. Quality of Life in MPN Comes of Age as a Therapeutic Target. Curr Hematol Malig Rep. 2014 Sep 28.
    View PubMed
  3. Mascarenhas JO, Cross NC, Mesa RA. The future of JAK inhibition in myelofibrosis and beyond. Blood Rev. 2014 Sep; 28(5):189-96. Epub 2014 Jun 28.
    View PubMed
  4. Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Harrison C, Hehlmann R, Hermouet S, Kiladjian JJ, Kroger N, Mesa R, Mc Mullin MF, Pardanani A, Passamonti F, Samuelsson J, Vannucchi AM, Reiter A, Silver Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia. 2014 Aug 25.
    View PubMed
  5. Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, Valdez R, Camoriano J, Fauble V, Tiedemann RE, Qiu YH, Coombes KR, Cardone M, Braggio E, Yin H, Azorsa DO, Mesa RA, Stewart AK, Tibes R. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014 Aug; 28(8):1657-65. Epub 2014 Jan 23.
    View PubMed
  6. Geyer HL, Mesa RA, et al. Therapy for myeloproliferative neoplasms: when, which agent and how? Blood (accepted for publication). 2014 Aug.
  7. Bogenberger JM, Delman D, Hansen N, Valdez R, Fauble V, Mesa RA, Tibes R. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma. 2014 Jun 17; 1-4.
    View PubMed
  8. Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernandez-Maraver D, Dohner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Vannucchi AM, Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014 Jun 12; 123(24):3803-10. Epub 2014 Feb 19.
    View PubMed
  9. Yan M, Geyer H, Mesa R, Atallah E, Callum J, Bartoszko J, Yee K, Maganti M, Wong F, Gupta V. Clinical Features of Patients With Philadelphia-Negative Myeloproliferative Neoplasms Complicated by Portal Hypertension. Clin Lymphoma Myeloma Leuk. 2014 Jun 11.
    View PubMed
  10. Rosenthal A, Mesa RA. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. Expert Opin Pharmacother. 2014 Jun; 15(9):1265-76. Epub 2014 Apr 25.
    View PubMed
  11. Geyer H, Mesa RA. Assessing disease burden in patients with classic MPNs. Best Pract Res Clin Haematol. 2014 Jun; 27(2):107-19. Epub 2014 Jul 18.
    View PubMed
  12. Tefferi A, Hudgens S, Mesa R, Peter Gale R, Verstovsek S, Passamonti F, Cervantes F, Rivera C, Tencer T, Khan ZM. Use of the functional assessment of cancer therapy-anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clin Ther. 2014 Apr 1; 36(4):560-6. Epub 2014 Mar 14.
    View PubMed
  13. Leal AD, Thompson CA, Wang AH, Vierkant RA, Habermann TM, Ross JA, Mesa RA, Virnig BA, Cerhan JR. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort. Int J Cancer. 2014 Apr 1; 134(7):1741-50. Epub 2013 Oct 15.
    View PubMed
  14. Chaudhuri L, Vincelette ND, Koh BD, Naylor RM, Flatten KS, Peterson KL, McNally A, Gojo I, Karp JE, Mesa RA, Sproat LO, Bogenberger JM, Kaufmann SH, Tibes R. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. Haematologica. 2014 Apr; 99(4):688-96. Epub 2013 Oct 31
    View PubMed
  15. Mesa RA. How I Manage Essential Thrombocythemia. Clin Oncol News. 2014 Mar.
  16. Gowin K, Mesa R. Management of thrombocythemia. F1000Res. 2014; 3:227. Epub 2014 Sep 29.
    View PubMed
  17. Verstovsek S, Quintas-Cardama A, Kantarjian HM, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Sun W, Sarlis NJ, Sandor V, Levy RS, Mesa RA. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. OncoTargets and Therapy. 2014; 7:13-21.
  18. Fryzek, Mehta J, Usman I, Wang H, Mesa RA. Health Resource Utilization and Cost Associated with Myeloproliferative neoplasms (MPN) in a Large United States Health Plan. Leuk Lymphoma (accepted). 2014.
  19. Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014; 55(3):595-600.
  20. Tibes R, Mesa RA. Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies. J Hematol Oncol. 2014; 7:18. Epub 2014 Mar 05.
    View PubMed
  21. Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, Levy R, Siulnik A, Gupta V, Khan M, DiPersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. 2014; 99(2):291-8.
  22. Titmarsh GJ, Duncombe AS, Mcmullin MF, O'Rorke M, Mesa R, De Vocht F, Horan S, Fritschi L, Clarke M, Anderson LA. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014; 89(6):581-7.
  23. Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014; 92(4):289-97.
  24. Padrnos L, Mesa RA. A closer look at pacritinib: A JAK2/FLT3 inhibitor for the treatment of myelofibrosis. Expert Opinion on Orphan Drugs. 2014; 2(7):725-33.
  25. Gowin K, Emanuel R, Geyer H, Mesa RA. The new landscape of therapy for myelofibrosis. Curr Hematol Malig Rep. 2013 Dec; 8(4):325-32.
    View PubMed
  26. Gowin K, Mesa R. Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis. Expert Opin Investig Drugs. 2013 Dec; 22(12):1603-11. Epub 2013 Sep 25.
    View PubMed
  27. Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN. Ruxolitinib for myelofibrosis--an update of its clinical effects. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):638-45. Epub 2013 Oct 02.
    View PubMed
  28. Mesa RA. Presentation and symptom burden of polycythemia vera. MPN Updates. 2013 Dec(1):1-7.
  29. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Dec; 98(12):1865-71. Epub 2013 Sep 13.
    View PubMed
  30. Harrison C, Mesa R, Ross D, Mead A, Keohane C, Gotlib J, Verstovsek S. Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Rev Hematol. 2013 Oct; 6(5):511-23. Epub 2013 Oct 02.
    View PubMed
  31. Abelsson J, Andreasson B, Samuelsson J, Hultcrantz M, Ejerblad E, Johansson B, Emanuel R, Mesa R, Johansson P. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leuk Lymphoma. 2013 Oct; 54(10):2226-30. Epub 2013 Jul 29.
    View PubMed
  32. Mesa RA, Silver RT, Verstovsek S, Mascarenhas J, Kessler CM, Rondelli D, Goldberg JD, Marchioli R, Demakos EP, Silverman LR, Hoffman R. Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial. Haematologica. 2013 Sep; 98(9):1421-3. Epub 2013 Jun 28.
    View PubMed
  33. Tibes R, Mesa RA. Emerging drugs for polycythemia vera. Expert Opin Emerg Drugs. 2013 Sep; 18(3):393-404.
    View PubMed
  34. Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R, Gisslinger H, Kroger N, Thiele J, Barbui T, Barosi G. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013 Aug 22; 122(8):1395-8. Epub 2013 Jul 09.
    View PubMed
  35. Mesa RA, Shields A, Hare T, Erickson-Viitanen S, Sun W, Sarlis NJ, Sandor V, Levy RS, Verstovsek S. Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. Leuk Res. 2013 Aug; 37(8):911-6. Epub 2013 May 17.
    View PubMed
  36. DeAngelo DJ, Mesa RA, Fiskus W, Tefferi A, Paley C, Wadleigh M, Ritchie EK, Snyder DS, Begna K, Ganguly S, Ondovik MS, Rine J, Bhalla KN. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol. 2013 Aug; 162(3):326-35. Epub 2013 May 23.
    View PubMed
  37. Harrison CN, Mesa RA, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley-Merriman C, Hunter DS, Levy RS, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi AM. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013 Jul; 162(2):229-39. Epub 2013 May 14.
    View PubMed
  38. Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013 Jun 6; 121(23):4778-81. Epub 2013 Apr 16.
    View PubMed
  39. Cherington C, Schuster SR, Kundranda M, Valdez R, Mesa RA, Northfelt DW. A surprising cause of masses in the chest. Am J Hematol. 2013 Jun; 88(6):518-21. Epub 2012 Oct 17.
    View PubMed
  40. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol. 2013 May; 161(4):508-16. Epub 2013 Mar 11.
    View PubMed
  41. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM, Verstovsek S. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013 Apr 1; 31(10):1285-92. Epub 2013 Feb 19.
    View PubMed
  42. Hensley B, Geyer H, Mesa R. Polycythemia vera: current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013 Apr; 14(5):609-17.
    View PubMed
  43. Emanuel RM, Geyer HL, Mesa RA. Ruxolitinib as an emerging treatment in myelofibrosis. Dovepress Journal. 2013 Mar 11; 2013(3):11-8.
  44. Noel P, Mesa RA. Eosinophilic myeloid neoplasms. Curr Opin Hematol. 2013 Mar; 20(2):157-62.
    View PubMed
  45. Mesa RA. The evolving treatment paradigm in myelofibrosis. Leuk Lymphoma. 2013 Feb; 54(2):242-51. Epub 2012 Aug 14.
    View PubMed
  46. Geyer HL, Mesa RA. JAK2 Inhibition: Current Roles in Myelofibrosis and Initial Lessons Learned from Mexico. Revista de Hematología de México. 2013 Jan-Mar; 14(1).
  47. Fryzek J, Mesa RA, et al. Epidemiology of myelofibrosis (MF), essential thrombocythemia (ET), and polycythemia vera (PV) in the European Union (EU). Eur J Haematol. 2013.
  48. Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther. 2013; 7:13-21. Epub 2013 Dec 17.
    View PubMed
  49. Bollin KB, Geyer HL, Mesa RA. Pomalidomide and the growing role of immunomodulatory agents in the treatment of myelofibrosis. Expert Opinion on Orphan Drugs. 2013; 1(7):539-47.
  50. Keohane C, Mesa R, Harrison C. The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms. Am Soc Clin Oncol Educ Book. 2013; 301-5.
    View PubMed
  51. Mesa RA, Kiladjian J, Verstovsek S, et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica (accepted). 2013.
  52. Kantarjian HM, Mesa RA. Use of the JAK1/JAK2 inhibitor ruxolitinib in the treatment of patients with myelofibrosis. Community Oncology. 2013.
  53. Mesa RA, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol. 2013; 6:79. Epub 2013 Oct 22.
    View PubMed
  54. Tibes R, Bogenberger JM, Geyer HL, Mesa RA. JAK2 inhibitors in the treatment of myeloproliferative neoplasms. Expert Opin Investig Drugs. 2012 Dec; 21(12):1755-74. Epub 2012 Sep 19.
    View PubMed
  55. Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012 Nov 20; 30(33):4098-103. Epub 2012 Oct 15.
    View PubMed
  56. Gowin K, Thapaliya P, Samuelson J, Harrison C, Radia D, Andreasson B, Mascarenhas J, Rambaldi A, Barbui T, Rea CJ, Camoriano J, Gentry A, Kiladjian JJ, O'Connell C, Mesa R. Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica. 2012 Oct; 97(10):1570-3. Epub 2012 Mar 14
    View PubMed
  57. Tibes R, Bogenberger JM, Benson KL, Mesa RA. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms. Mol Diagn Ther. 2012 Oct; 16(5):269-83.
    View PubMed
  58. Cherington C, Slack JL, Leis J, Adams RH, Reeder CB, Mikhael JR, Camoriano J, Noel P, Fauble V, Betcher J, Higgins MS, Gillette-Kent G, Tremblay LD, Peterson ME, Olsen JJ, Tibes R, Mesa RA. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res. 2012 Sep; 36(9):1147-51. Epub 2012 May 11.
    View PubMed
  59. Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe A, Green AR, Michaeel NG, Gilleece MH, Hall GW, Knapper S, Mead A, Mesa RA, Sekhar M, Wilkins B, Harrison CN, Writing group: British Committee for Standards in Haematology. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol. 2012 Aug; 158(4):453-71. Epub 2012 Jun 1
    View PubMed
  60. Tibes R, Mesa RA. Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques. Leuk Res. 2012 Jun; 36(6):664-71. Epub 2012 Mar 28.
    View PubMed
  61. Harrison C, Verstovsek S, McMullin MF, Mesa R. Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? Br J Haematol. 2012 May; 157(4):426-37. Epub 2012 Mar 29.
    View PubMed
  62. Geyer HL, Tibes R, Mesa RA. JAK2 inhibitors and their impact in myeloproliferative neoplasms. Hematology. 2012 Apr; 17 Suppl 1:S129-32.
    View PubMed
  63. Tibes R, Bogenberger JM, Chaudhuri L, Hagelstrom RT, Chow D, Buechel ME, Gonzales IM, Demuth T, Slack J, Mesa RA, Braggio E, Yin HH, Arora S, Azorsa DO. RNAi screening of the kinome with cytarabine in leukemias. Blood. 2012 Mar 22; 119(12):2863-72. Epub 2012 Jan 20.
    View PubMed
  64. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1; 366(9):799-807.
    View PubMed
  65. Kundranda MN, Tibes R, Mesa RA. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work? Curr Hematol Malig Rep. 2012 Mar; 7(1):78-86.
    View PubMed
  66. Johansson P, Mesa R, Scherber R, Abelsson J, Samuelsson J, Birgegard G, Andreasson B. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leuk Lymphoma. 2012 Mar; 53(3):441-4. Epub 2011 Oct 24.
    View PubMed
  67. Mesa RA, Yasothan U, Kirkpatrick P. Ruxolitinib. Nat Rev Drug Discov. 2012 Feb; 11(2):103-4 Epub 2012 Feb 1.
    View PubMed
  68. Geyer H, Karlin N, Palen B, Mesa R. Asian-variant intravascular lymphoma in the African race. Rare Tumors. 2012 Jan 2; 4(1):e10. Epub 2012 Mar 19.
    View PubMed
  69. Begna KH, Pardanani A, Mesa R, Litzow MR, Hogan WJ, Hanson CA, Tefferi A. Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol. 2012 Jan; 87(1):66-8. Epub 2011 Nov 12.
    View PubMed
  70. Fauble V, Leis J, Mesa RA. Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors. Leukemia Supplements. 2012; 1:S2-7.
  71. Raza A, Galili N, Mulford D, Smith SE, Brown GL, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Garcia-Manero G, Mesa RA. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). J Hematol Oncol. 2012; 5:18. Epub 2012 Apr 30.
    View PubMed
  72. Tibes R, Mesa R. JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rational and clinical data. Clin Invest. 2011 Dec; 1(12):1681-93.
  73. Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek S. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011 Nov 1; 117(21):4869-77. Epub 2011 Apr 08.
    View PubMed
  74. Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, Ivy SP, Ames MM, Adjei AA, Erlichman C, Karnitz LM. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica. 2011 Nov; 96(11):1619-26. Epub 2011 Jul 26.
    View PubMed
  75. Gregory SA, Mesa RA, Hoffman R, Shammo JM. Clinical and laboratory features of myelofibrosis and limitations of current therapies. Clin Adv Hematol Oncol. 2011 Sep; 9(9 Suppl 22):1-16.
    View PubMed
  76. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011 Jul 14; 118(2):401-8. Epub 2011 May 02.
    View PubMed
  77. Tibes R, Mesa RA. Blood consult: resistant and progressive essential thrombocythemia. Blood. 2011 Jul 14; 118(2):240-2. Epub 2011 May 23.
    View PubMed
  78. Tibes R, Mesa RA. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy? Leuk Lymphoma. 2011 Jul; 52(7):1178-87. Epub 2011 May 23.
    View PubMed
  79. Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011 May 5; 117(18):4706-15. Epub 2011 Mar 09.
    View PubMed
  80. Van Etten RA, Koschmieder S, Delhommeau F, Perrotti D, Holyoake T, Pardanani A, Mesa R, Green T, Ibrahim AR, Mughal T, Gale RP, Goldman J. The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica. 2011 Apr; 96(4):590-601. Epub 2011 Jan 17.
    View PubMed
  81. Scherber R, Mesa RA. Future therapies for the myeloproliferative neoplasms. Curr Hematol Malig Rep. 2011 Mar; 6(1):22-7.
    View PubMed
  82. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kroger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011 Feb 20; 29(6):761-70. Epub 2011 Jan 04.
    View PubMed
  83. Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, Tefferi A. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2011 Feb; 25(2):301-4. Epub 2010 Nov 05.
    View PubMed
  84. Mesa RA, Green A, Barosi G, Verstovsek S, Vardiman J, Gale RP. MPN-associated myelofibrosis (MPN-MF). Leuk Res. 2011 Jan; 35(1):12-3. Epub 2010 Aug 04.
    View PubMed
  85. Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, Geyer S, Mesa RA. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol. 2011 Jan; 86(1):96-8.
    View PubMed
  86. Mesa R. Individualized Care Plans for Myelofibrosis. Haematologica. 2011; 96(Suppl 1):264-272.
  87. Scherber R, Mesa RA. Relevance of Weight Loss, Splenomegaly, and Hypocholesterolemia in the Treatment of Myeloproliferative Neoplasms: Implications for a JAK2 Inhibitor Era US Oncology and Hematology. 2011; 7(1):61-63.
  88. Mesa RA, Yao X, Cripe LD, Li CY, Litzow M, Paietta E, Rowe JM, Tefferi A, Tallman MS. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. 2010 Nov 25; 116(22):4436-8. Epub 2010 Jul 22.
    View PubMed
  89. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16; 363(12):1117-27.
    View PubMed
  90. Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs. 2010 Jun; 13(6):394-403.
    View PubMed
  91. Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T, Weiss T, Nowak D, Koren-Michowitz M, Kato M, Sanada M, Shih LY, Nagler A, Raynaud SD, Muller-Tidow C, Mesa R, Haferlach T, Gilliland DG, Tefferi A, Ogawa S, Koeffler HP. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2010 Apr 8; 115(14):2882-90. Epub 2010 Jan 12.
    View PubMed
  92. Mesa RA. New drugs for the treatment of myelofibrosis. Curr Hematol Malig Rep. 2010 Jan; 5(1):15-21.
    View PubMed
  93. Mesa RA. Assessing new therapies and their overall impact in myelofibrosis. Hematology Am Soc Hematol Educ Program. 2010; 2010:115-21.
    View PubMed
  94. Goldman JM, Green AR, Holyoake T, Jamieson C, Mesa R, Mughal T, Pellicano F, Perrotti D, Skoda R, Vannucchi AM. Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia. 2009 Oct; 23(10):1708-15. Epub 2009 Jul 30.
    View PubMed
  95. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20; 27(27):4563-9. Epub 2009 Aug 03.
    View PubMed
  96. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009 Sep; 33(9):1199-203. Epub 2009 Feb 27.
    View PubMed
  97. Mesa RA, Tefferi A. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep; 14(3):471-9.
    View PubMed
  98. Mesa R, Gale RP. Hypothesis: how do JAK2-inhibitors work in myelofibrosis. Leuk Res. 2009 Sep; 33(9):1156-7. Epub 2009 May 17.
    View PubMed
  99. Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood. 2009 May 28; 113(22):5394-400. Epub 2009 Mar 30.
    View PubMed
  100. Tefferi A, Mesa RA, Pardanani A, Hussein K, Schwager S, Hanson CA, Steensma DP. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol. 2009 May; 84(5):265-7.
    View PubMed
  101. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009 May; 23(5):905-11. Epub 2009 Mar 05.
    View PubMed
  102. Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson CM, Ketterling RP, Hanson CA, Van Dyke DL, Tefferi A. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol. 2009 Apr; 82(4):255-9. Epub 2008 Feb 10
    View PubMed
  103. Mesa RA. New drugs for the therapy of myelofibrosis. Current Hematologic Malignancy Reports. 2009; 5(1).
  104. Hussein K, Ketterling RP, Dewald GW, Van Dyke DL, Mesa R, Hanson CA, Tefferi A. Peripheral blood cytogenetic studies in myelofibrosis: overall yield and comparison with bone marrow cytogenetic studies. Leuk Res. 2008 Oct; 32(10):1597-600. Epub 2008 Feb 1
    View PubMed
  105. Mott JL, Bronk SF, Mesa RA, Kaufmann SH, Gores GJ. BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol Cancer Ther. 2008 Aug; 7(8):2339-47.
    View PubMed
  106. Huang J, Li CY, Mesa RA, Wu W, Hanson CA, Pardanani A, Tefferi A. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer. 2008 Jun 15; 112(12):2726-32.
    View PubMed
  107. Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanani A, Tefferi A. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol. 2008 May; 83(5):363-5.
    View PubMed
  108. Steensma DP, Heptinstall KV, Johnson VM, Novotny PJ, Sloan JA, Camoriano JK, Niblack J, Bennett JM, Mesa RA. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res. 2008 May; 32(5):691-8. Epub 2007 Dec 4
    View PubMed
  109. Tefferi A, Gangat N, Wolanskyj AP, Schwager S, Pardanani A, Lasho TL, Mesa R, McClure RF, Li CY, Hanson CA. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. Eur J Haematol. 2008 May; 80(5):386-90. Epub 2008 Jan 23.
    View PubMed
  110. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, Wu W, Hanson CA, Pardanani A. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008 Apr; 22(4):756-61. Epub 2008 Jan 24.
    View PubMed
  111. Mesa R. Myeloproliferative disorder-associated massive splenomegaly. Clin Adv Hematol Oncol. 2008 Apr; 6(4):278, 281-2.
    View PubMed
  112. Mesa RA. New insights into the pathogenesis and treatment of chronic myeloproliferative disorders. Curr Opin Hematol. 2008 Mar; 15(2):121-6.
    View PubMed
  113. Kroger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia. 2008 Mar; 22(3):474-86. Epub 2008 Jan 10.
    View PubMed
  114. Knoll B, Rea DJ, Szoztek J, Nagorney DS, Tefferi A, Mesa RA. Extramedullary hematopoiesis. Am J Hematol. 2008 Feb; 83(2):171.
    View PubMed
  115. Mesa RA. Imatinib Mesylate for the BCR-ABL Negative Myeloproliferative Disorders. Biologics: Targets and Therapy. 2008.
  116. Mesa RA. Blastic Transformation in Myeloproliferative Disorders Haematologica. 2008; 2(Suppl1):216-223.
  117. Elliott MA, Verstovsek S, Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007 Nov; 31(11):1503-9. Epub 2007 Mar 29.
    View PubMed
  118. Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J. 2007 Nov-Dec; 13(6):377-83.
    View PubMed
  119. Pardanani A, Lasho TL, Finke C, Mesa RA, Hogan WJ, Ketterling RP, Gilliland DG, Tefferi A. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells. 2007 Sep; 25(9):2358-62. Epub 2007 May 31.
    View PubMed
  120. Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE, Erlichman C, Wright J, Pardanani A, Lasho T, Finke C, Li CY, Tefferi A. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia. 2007 Sep; 21(9):1964-70. Epub 2007 Jun 21.
    View PubMed
  121. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007 Aug 15; 110(4):1092-7. Epub 2007 May 08.
    View PubMed
  122. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007 Aug; 21(8):1658-68. Epub 2007 May 31.
    View PubMed
  123. Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia. 2007 Aug; 21(8):1827-8. Epub 2007 Apr 26.
    View PubMed
  124. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, Levine R, Le Bousse-Kerdiles MC, Wadleigh M, Campbell PJ, Silver RT, Vannucchi AM, Deeg HJ, Gisslinger H, Thomas D, Odenike O, Solberg LA, Gotlib J, Hexner E, Nimer SD, Kantarjian H, Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007 Jun; 31(6):737-40. Epub 2007 Jan 08.
    View PubMed
  125. Mesa RA. Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders. Biologics. 2007 Jun; 1(2):129-38.
    View PubMed
  126. Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A, Mesa RA. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 2007 May 15; 109(10):2083-8.
    View PubMed
  127. Mesa RA, Quintas-Cardama A, Verstovsek S. Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia. Curr Hematol Malig Rep. 2007 Feb; 2(1):25-33.
    View PubMed
  128. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) - an international internet-based survey of 1179 MPD patients. Cancer. 2007 Jan 1; 109(1):68-76.
    View PubMed
  129. Mesa RA. Management of MPDs: Update on the Latest Development on Diagnosis and Treatment Korean Journal of Hematology. 2007; 42 (Suppl 2):2-4.
  130. Mesa RA. Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program. 2007; 355-62.
    View PubMed
  131. Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gilliland DG, Tefferi A. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol. 2006 Dec; 135(5):683-7.
    View PubMed
  132. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006 Nov 15; 108(10):3472-6. Epub 2006 Jul 25.
    View PubMed
  133. Mesa RA, Powell H, Lasho T, Dewald G, McClure R, Tefferi A. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk Res. 2006 Nov; 30(11):1457-60. Epub 2006 Mar 23.
    View PubMed
  134. Mesa RA, Tefferi A, Lasho TS, Loegering D, McClure RF, Powell HL, Dai NT, Steensma DP, Kaufmann SH. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. Leukemia. 2006 Oct; 20(10):1800-8. Epub 2006 Jul 27.
    View PubMed
  135. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA Jr, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H, International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006 Sep 1; 108(5):1497-503. Epub 2006 May 04.
    View PubMed
  136. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006 Aug 15; 108(4):1158-64. Epub 2006 Apr 11.
    View PubMed
  137. Mesa RA. Practical management of classical myeloproliferative disorder patients: a clinician's guide. Future Oncol. 2006 Aug; 2(4):515-24.
    View PubMed
  138. Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006 Jul 15; 107(2):361-70.
    View PubMed
  139. Gangat N, Wolanskyj AP, Schwager SM, Mesa RA, Tefferi A. Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia. Cancer. 2006 Jun 1; 106(11):2406-11.
    View PubMed
  140. Tefferi A, Dingli D, Li CY, Mesa RA. Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates. Leuk Res. 2006 Jun; 30(6):677-80. Epub 2005 Nov 08.
    View PubMed
  141. Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer. 2006 May 1; 106(9):1985-9.
    View PubMed
  142. Tefferi A, Strand JJ, Lasho TL, Elliott MA, Li CY, Mesa RA, Dewald GW. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy. Cancer. 2006 Apr 15; 106(8):1739-43.
    View PubMed
  143. Mesa RA. Tipifarnib: farnesyl transferase inhibition at a crossroads. Expert Rev Anticancer Ther. 2006 Mar; 6(3):313-9.
    View PubMed
  144. Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer. 2006 Feb 1; 106(3):623-30.
    View PubMed
  145. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, Li CY, Wadleigh M, Lee SJ, Gilliland DG. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer. 2006 Feb 1; 106(3):631-5.
    View PubMed
  146. Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, Tefferi A, Elliot MA, Kaufmann SH, Mesa RA, Litzow MR. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia. 2006 Jan; 20(1):29-34.
    View PubMed
  147. Mesa RA, Barosi G, Cervantes F, Reilly JT, Tefferi A. Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options. Best Pract Res Clin Haematol. 2006; 19(3):495-517.
    View PubMed
  148. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol. 2005 Nov; 131(3):320-8.
    View PubMed
  149. Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, Wolanskyj AP, Steensma DP, Mesa R, Gilliland DG. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol. 2005 Oct; 131(2):166-71.
    View PubMed
  150. Mesa RA, Tefferi A. Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia. Semin Oncol. 2005 Aug; 32(4):403-13.
    View PubMed
  151. Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SJ, Dai NT, Heldebrant MP, Vroman BT, Smith BD, Karp JE, Eyck CJ, Erlichman C, Kaufmann SH, Karnitz LM. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood. 2005 Jul 1; 106(1):318-27. Epub 2005 Mar 22.
    View PubMed
  152. Goel A, Dispenzieri A, Greipp PR, Witzig TE, Mesa RA, Russell SJ. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp Hematol. 2005 Jul; 33(7):784-95.
    View PubMed
  153. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, Boggon TJ, Wlodarska L, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr; 7(4):387-97.
    View PubMed
  154. Mesa RA, Li CY, Kettering RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005 Feb 1; 105(3):973-7.
    View PubMed
  155. Faoro LN, Tefferi A, Mesa RA. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol. 2005 Feb; 74(2):117-20.
    View PubMed
  156. Arora B, Sirhan S, Hoyer JD, Mesa RA, Tefferi A. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br J Haematol. 2005 Jan; 128(1):42-8.
    View PubMed
  157. Ho CL, Arora B, Hoyer JD, Wellik LE, Mesa RA, Tefferi A. Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia. Eur J Haematol. 2005 Jan; 74(1):35-9.
    View PubMed
  158. Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur J Haematol. 2005 Jan; 74(1):47-53.
    View PubMed
  159. Arora B, Mesa R, Tefferi A. Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia. Leuk Lymphoma. 2004 Dec; 45(12):2373-86.
    View PubMed
  160. Arora B, Ho CL, Hoyer JD, Mesa RA, Tefferi A. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia. Haematologica. 2004 Dec; 89(12):1454-8.
    View PubMed
  161. Elliott MA, Wolf RC, Hook CC, Pruthi RK, Heit JA, Letendre LL, Tefferi A, Kaufmann SH, Mesa RA, Litzow MR. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: Incidence, risk factors, and possible role of antithrombin. Leukemia & Lymphoma. 2004 Aug; 45(8):1545-9.
    View PubMed
  162. Dingli D, Mesa RA, Tefferi A. Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment. Intern Med. 2004 Jul; 43(7):540-7.
    View PubMed
  163. Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc. 2004 Jul; 79(7):883-9.
    View PubMed
  164. Tefferi A, Lasho TL, Wolanskyj AP, Mesa RA. Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood. 2004 May 1; 103(9):3547-8. Epub 2003 Dec 30.
    View PubMed
  165. Koch CA, Li CY, Mesa RA, Tefferi A. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc. 2003 Oct; 78(10):1223-33.
    View PubMed
  166. Lindor NM, Dozois R, Nelson H, Wolff B, King J, Boardman L, Wilson M, Greene MH, Karnes W, Mesa R, Welch T, Edmonson J, Limburg P. Desmoid tumors in familial adenomatous polyposis: a pilot project evaluating efficacy of treatment with pirfenidone. Am J Gastroenterol. 2003 Aug; 98(8):1868-74.
    View PubMed
  167. Mesa RA. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003. Current Hematology Reports. 2003 May; 2(3):264-70.
    View PubMed
  168. Mesa RA, Tefferi A, Gray LA, Reeder T, Schroeder G, Kaufmann SH. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia. 2003 May; 17(5):849-55.
    View PubMed
  169. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003 Apr 1; 101(7):2534-41. Epub 2002 Nov 27.
    View PubMed
  170. Mesa RA. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders. Int J Hematol. 2002 Aug; 76(Suppl 2):193-203.
    View PubMed
  171. Mesa RA. The therapy of myelofibrosis: Targeting pathogenesis. Int J Hematol. 2002 Aug; 76(Suppl 2):296-304.
    View PubMed
  172. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002 Jul; 8(7):2210-6.
    View PubMed
  173. Mesa RA, Hanson CA, Li CY, Yoon SY, Rajkumar SV, Schroeder G, Tefferi A. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood. 2002 Jun 1; 99(11):4131-7.
    View PubMed
  174. Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA, Pardanani A, Ansell SM, Call TG, Colon-Otero G, Schroeder G, Hanson CA, Dewald GW, Kaufmann SH. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood. 2002 May 15; 99(10):3854-6.
    View PubMed
  175. Elliott MA, Mesa RA, Li CY, Hook CC, Ansell SM, Levitt RM, Geyer SM, Tefferi A. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol. 2002 May; 117(2):288-96.
    View PubMed
  176. Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood. 2002 Mar 15; 99(6):2252-4.
    View PubMed
  177. Rajkumar SV, Mesa RA, Tefferi A. A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies. J Hematother Stem Cell Res. 2002 Feb; 11(1):33-47.
    View PubMed
  178. Mesa RA, Tefferi A. Palliative splenectomy in myelofibrosis with myeloid metaplasia. Leuk Lymphoma. 2001 Sep-Oct; 42(5):901-11.
    View PubMed
  179. Mesa RA, Tefferi A, Elliott MA, Hoagland HC, Call TG, Schroeder GS, Yoon SY, Li CY, Gray LA, Margolin S, Hook CC. A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001 Jul; 114(1):111-3.
    View PubMed
  180. Mesa RA, Li CY, Schroeder G, Tefferi A. Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood. 2001 Jun 1; 97(11):3665-7.
    View PubMed
  181. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001 Jun; 113(3):763-71.
    View PubMed
  182. Tefferi A, Jimenez T, Gray LA, Mesa RA, Chen MG. Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. Eur J Haematol. 2001 Jan; 66(1):37-42.
    View PubMed
  183. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood. 2000 Nov 15; 96(10):3374-80.
    View PubMed
  184. Mesa RA, Elliott MA, Tefferi A. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia. Blood Rev. 2000 Sep; 14(3):121-9.
    View PubMed
  185. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000 Apr 1; 95(7):2226-33.
    View PubMed
  186. Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 1999 Sep; 106(3):682-8.
    View PubMed
  187. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol. 1999 May; 61(1):10-5.
    View PubMed
  188. Mesa RA, Edell ES, Dunn WF, Edwards WD. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc. 1998 Jan; 73(1):37-45.
    View PubMed
  189. Tefferi A, Bartholmai BJ, Witzig TE, Jenkins RB, Li CY, Hanson CA, Mesa RA, Phyliky RL. Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet. 1997 Jun; 95(2):173-7.
    View PubMed
  190. Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Semin Thromb Hemost. 1997; 23(4):379-83.
    View PubMed